Our Science – Kummar Website

Shivaani Kummar, M.D.

Medical Oncology Branch and Affiliates Developmental Therapeutics Section Staff Clinician National Cancer Institute Building 10, Room 12N226 9000 Rockville Pike Bethesda, MD 20892 Phone:   301-435-5402 Fax:   301-496-0047 E-Mail:   kummars@mail.nih.gov

Biography

Dr. Shivaani Kummar received her medical degree from Lady Hardinge Medical College, New Delhi, India and her Internal Medicine Residency training from Emory University, Atlanta, Georgia. Upon completion of her fellowship training in Medical Oncology and Hematology from the National Institutes of Health, Bethesda, MD, she joined Yale Cancer Center, Yale University, New Haven, Connecticut as an Assistant Professor in Medical Oncology. During her time at Yale, she worked closely with the Department of Pharmacology, Yale University to facilitate bringing new agents to clinical trials. At present, she is a Staff Clinician, Medical Oncology Branch, National Cancer Institute and works on early drug development in oncology.

Research

View Dr. Kummar's Current Clinical Trials

Dr Kummar's clinical interests focus on two major areas: Early drug development and the treatment of Colorectal Cancer. She is the Principal Investigator on a number of clinical protocols including the first Phase 0 trial in Oncology conducted by the NCI. She has published in major peer-reviewed journals in the field of oncology. Dr Kummar is a member of the American Society of Clinical Oncology and the American Association for Cancer Research.

Selected publications:
Book Chapters:
1. Murgo AJ, Kummar S, Gutierrez M, Tomaszewski JE, Doroshow JH. Principles of Molecularly Targeted Therapy: Present and Future. Clinical Oncology (Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG); 4th Edition, 2008.

2. Kummar S, Noronha V, Chu E. Antimetabolites. Cancer Principles and Practice of Oncology (Devita VT, Hellman S, Rosenberg SA); 7th Edition, 2004.


Selected Journal publications:
1.Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer. 2007;7(2):131-9.

2.Murgo AJ, Kummar S, Rubinstein L, Gutierrez M, Collins J, Kinders R, Parchment RE, Ji J, Steinberg SM, Yang SX, Hollingshead M, Chen A, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH. Designing Phase 0 Cancer Clinical Trials. Clin Cancer Res. 2008;14(12):3675-82.

3. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Clin Pract Oncol. 2008 (in press).

4. Kummar S, Doroshow JH, Tomaszewski JE, Calvert HA, Lobbezoo M, Giaccone G. Phase 0 clinical trials: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 2008 (in press).


5.Kummar S, Gutierrez ME, Doroshow JH, Murgo A. Drug Development in Oncology: Classical Cytotoxics and Molecularly Targeted Agents. British Journal of Clinical Pharmacology, 2006; 62(1):15-26.

6.O'Mahony D, Kummar S, Gutierrez, M. Non-Small Cell Lung Cancer Vaccine Therapy: A concise review. J Clin Oncol. 2005;23(35):9022-8.

This page was last updated on 12/9/2008.